Aridis Pharma COVID-19 Antibody Neutralizes Omicron Variant In Animal Study

Aridis Pharmaceuticals Inc's (NASDAQ: ARDS) fully human monoclonal antibodies (mAbs) in the AR-701 cocktail has been shown to neutralize the SARS-CoV-2 omicron variant.

• Both mAbs conferred complete protection against Omicron infected animals when given either parenterally or by intranasal administration.

• Both mAbs in the AR-701 cocktail, i.e., AR-720 and AR-703, neutralized all authentic SARS-CoV-2 beta, gamma, delta, epsilon, and Omicron variants in vitro.

• Aridis Pharmaceuticals has recently received a .9 million grant from the Bill and Melinda Gates Foundation to evaluate the prevention of influenza and SARS-CoV-2 (COVID-19) viral transmission using inhaled delivery of monoclonal antibodies. ...